Manara - Qatar Research Repository
Browse
1/1
9 files

Prognostic tools and candidate drugs based on plasma proteomics of patients with severe COVID-19 complications

journal contribution
submitted on 2024-04-23, 09:16 and posted on 2024-04-23, 09:17 authored by Maryam A. Y. Al-Nesf, Houari B. Abdesselem, Ilham Bensmail, Shahd Ibrahim, Walaa A. H. Saeed, Sara S. I. Mohammed, Almurtada Razok, Hashim Alhussain, Reham M. A. Aly, Muna Al Maslamani, Khalid Ouararhni, Mohamad Y. Khatib, Ali Ait Hssain, Ali S. Omrani, Saad Al-Kaabi, Abdullatif Al Khal, Asmaa A. Al-Thani, Waseem Samsam, Abdulaziz Farooq, Jassim Al-Suwaidi, Mohammed Al-Maadheed, Heba H. Al-Siddiqi, Alexandra E. Butler, Julie V. Decock, Vidya Mohamed-Ali, Fares Al-Ejeh

COVID-19 complications still present a huge burden on healthcare systems and warrant predictive risk models to triage patients and inform early intervention. Here, we profile 893 plasma proteins from 50 severe and 50 mild-moderate COVID-19 patients, and 50 healthy controls, and show that 375 proteins are differentially expressed in the plasma of severe COVID-19 patients. These differentially expressed plasma proteins are implicated in the pathogenesis of COVID-19 and present targets for candidate drugs to prevent or treat severe complications. Based on the plasma proteomics and clinical lab tests, we also report a 12-plasma protein signature and a model of seven routine clinical tests that validate in an independent cohort as early risk predictors of COVID-19 severity and patient survival. The risk predictors and candidate drugs described in our study can be used and developed for personalized management of SARS-CoV-2 infected patients.

Other Information

Published in: Nature Communications
License: https://creativecommons.org/licenses/by/4.0
See article on publisher's website: https://dx.doi.org/10.1038/s41467-022-28639-4

History

Language

  • English

Publisher

Springer Nature

Publication Year

  • 2022

License statement

This Item is licensed under the Creative Commons Attribution 4.0 International License.

Institution affiliated with

  • Hamad Medical Corporation
  • Hamad General Hospital - HMC
  • Communicable Disease Center - HMC
  • Hazm Mebaireek General Hospital - HMC
  • Hamad Bin Khalifa University
  • Qatar Biomedical Research Institute - HBKU
  • College of Health and Life Sciences - HBKU
  • Qatar University
  • Biomedical Research Center - QU
  • Anti-Doping Laboratory Qatar - QA-DC

Usage metrics

    Qatar Biomedical Research Institute - HBKU

    Licence

    Exports

    RefWorks
    BibTeX
    Ref. manager
    Endnote
    DataCite
    NLM
    DC